Catalent nelle notizie
Partner di produzione per lo sviluppo di farmaci
Tamtam ha trovato 20 articoli recenti su Catalent.
- Catalent launches ten-month gene-to-drug substance programme for complex biologics
- Catalent, Inc. Launches Accelerated Gene-To-Drug Substance Program For Complex Biologics In The U.S
- Catalent Launches Accelerated Gene-to-Drug Substance Program for Complex Molecules in the U.S.
- Catalent Launches Accelerated Gene-to-Drug Substance Program in US for Complex Biologics
- ALK-Abelló (CPSE:ALK B) Expands Catalent Deal, Is The 32% Undervaluation Case Convincing?
- ALK expands Catalent partnership: what it means for Catalent stock
- ALK expands strategic tablet supply partnership with Catalent
- ALK expands Catalent partnership – guidance is maintained
- ALK Expands Tablet Supply Partnership With Catalent
- ALK, Catalent Expand Long-Term Contract Manufacturing Collaboration
- ALK expands strategic tablet supply partnership with Catalent
- Catalent stock reports USD 4.7 billion refinancing
- Catalent stock holds near its yearly low as earnings lag
- Catalent stock gains after FDA clears key manufacturing site
- Catalent stock holds steady as investors await fresh earnings and guidance
- Catalent lands $4.1B debt deal to expand biologics and oral drug capacity
- Catalent uses AI on Azure to strengthen quality management system processes
- Catalent Completes $4.1 Billion Debt Refinancing To Cut Annual Interest Expense By $100 Million
- Scholar Rock drops Catalent facility from marketing application for muscle weakness drug
- Catalent Completes Successful Debt Refinancing
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Catalent?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili